3. Subject selection: Cystic fibrosis patients who utilize the cystic fibrosis care center 
at Children’s Hospital Medical Center, meet criteria, and are willing to participate and 
sign a consent form. 
5.2.2 Inclusion Criteria 
1. Male or female aged > 18 years. 
2. Cystic fibrosis documented by a sweat chloride > 60meq/L by quantitative pilocarpine 
iontophoresis, homozygous for aF 508 marker by genetic testing and one finding 
consistent with the clinical diagnosis of CF. Genetic analysis documenting the aF 508 
mutation will be required. 
3. FVC > 40% of predicted value for sex, age, and height. (Value to be obtained on 
the day of admission, prior to initiation of study.) 
4. Oxygen saturation by pulse oximetry (after 10 minutes of rest) > 90% on room air. 
5. Female patients will be required to show documentation of sterility or to be using a 
form of contraception such as the oral contraceptive pill, the sheath, or the diaphragm. 
The last two methods will only be accepted if used in conjunction with a spermicidal 
jelly. Male patients will be required to use a sheath in conjunction with a spermicidal 
jelly. 
6. Female patients will have a negative serum pregnancy test. 
7. Seropositivity to adenovirus type 5. 
8. Patient legally able tq provide informed consent. 
5.2.3 Exclusion Criteria 
1. Hypercapnia defined as PCO 2 >50 mmHg on admission. 
2. Investigational drug use within 30 days prior to enrollment. 
3. History of hemoptysis requiring interventional therapy such as transfusion, emboliza- 
tion, or pulmonary resection within 180 days prior to admission. 
4. Identified focus of infection outside the respiratory tract. 
5. Current pneumothorax requiring chest tube. 
6. Presence of wild adenovirus infection (by culture or PCR). 
7. Abnormal coagulation studies (PT > 13 secs, on vitamin K 5 mg/day, platelet count 
< 200,000, or PTT > 35 secs.). 
Recombinant DNA Research, Volume 
17 
[393] 
